Radiosynthesis and Early Evaluation of a Positron Emission Tomography Imaging Probe [18F]AGAL Targeting Alpha-Galactosidase A Enzyme for Fabry Disease
-
Published:2023-10-18
Issue:20
Volume:28
Page:7144
-
ISSN:1420-3049
-
Container-title:Molecules
-
language:en
-
Short-container-title:Molecules
Author:
Lohith Talakad G.1, Kaittanis Charalambos1ORCID, Belanger Anthony P.2ORCID, Ahn Shin Hye2ORCID, Sandoval Phil1, Cohen Lawrence1ORCID, Rajarshi Girija1, Ruangsiriluk Wanida1ORCID, Islam Rizwana1, Winkelmann Christopher T.1, McQuade Paul1
Affiliation:
1. Takeda Pharmaceutical Co., Ltd., Cambridge, MA 02142, USA 2. Molecular Cancer Imaging Facility, Dana Farber Cancer Institute, Boston, MA 02210, USA
Abstract
Success of gene therapy relies on the durable expression and activity of transgene in target tissues. In vivo molecular imaging approaches using positron emission tomography (PET) can non-invasively measure magnitude, location, and durability of transgene expression via direct transgene or indirect reporter gene imaging in target tissues, providing the most proximal PK/PD biomarker for gene therapy trials. Herein, we report the radiosynthesis of a novel PET tracer [18F]AGAL, targeting alpha galactosidase A (α-GAL), a lysosomal enzyme deficient in Fabry disease, and evaluation of its selectivity, specificity, and pharmacokinetic properties in vitro. [18F]AGAL was synthesized via a Cu-catalyzed click reaction between fluorinated pentyne and an aziridine-based galactopyranose precursor with a high yield of 110 mCi, high radiochemical purity of >97% and molar activity of 6 Ci/µmol. The fluorinated AGAL probe showed high α-GAL affinity with IC50 of 30 nM, high pharmacological selectivity (≥50% inhibition on >160 proteins), and suitable pharmacokinetic properties (moderate to low clearance and stability in plasma across species). In vivo [18F]AGAL PET imaging in mice showed high uptake in peripheral organs with rapid renal clearance. These promising results encourage further development of this PET tracer for in vivo imaging of α-GAL expression in target tissues affected by Fabry disease.
Funder
Takeda Pharmaceutical Company Limited
Subject
Chemistry (miscellaneous),Analytical Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Molecular Medicine,Drug Discovery,Pharmaceutical Science
Reference21 articles.
1. Kok, K., Zwiers, K.C., Boot, R.G., Overkleeft, H.S., Aerts, J., and Artola, M. (2021). Fabry Disease: Molecular Basis, Pathophysiology, Diagnostics and Potential Therapeutic Directions. Biomolecules, 11. 2. Tuttolomondo, A., Simonetta, I., Riolo, R., Todaro, F., Di Chiara, T., Miceli, S., and Pinto, A. (2021). Pathogenesis and Molecular Mechanisms of Anderson-Fabry Disease and Possible New Molecular Addressed Therapeutic Strategies. Int. J. Mol. Sci., 22. 3. Potent and selective activity-based probes for GH27 human retaining alpha-galactosidases;Willems;J. Am. Chem. Soc.,2014 4. Galacto configured N-aminoaziridines: A new type of irreversible inhibitor of beta-galactosidases;Alcaide;Org. Biomol. Chem.,2015 5. A short synthesis of (+)-cyclophellitol;Hansen;J. Org. Chem.,2005
|
|